Titan Pharmaceuticals, Inc.SEC Filings
|
|
All SEC filings by Titan Pharmaceuticals, Inc. (TTNP) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 14, 2025 | |
| 10-Q | Quarterly report | View Diff | May 14, 2025 | |
| 10-K | Annual report | View Diff | Mar 20, 2025 | |
| 10-Q | Quarterly report | View Diff | Jan 3, 2025 | |
| NT 10-Q | Notice of late quarterly filing | Nov 15, 2024 | ||
| 10-Q | Quarterly report | View Diff | Aug 15, 2024 | |
| NT 10-Q | Notice of late quarterly filing | Aug 15, 2024 | ||
| 10-Q | Quarterly report | View Diff | May 15, 2024 | |
| 10-K | Annual report | View Diff | Apr 1, 2024 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2023 |
Events
| 8-K | Completion of Acquisition or Disposition of Assets | Oct 1, 2025 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | Aug 26, 2025 | ||
| 8-K | Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock | Jun 27, 2025 | ||
| 8-K | Submission of Matters to a Vote of Security Holders | Jun 18, 2025 | ||
| 8-K | Other Events | Jun 3, 2025 | ||
| 8-K | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard | Jun 2, 2025 | ||
| 8-K | Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock | Apr 22, 2025 | ||
| 8-K | Entry Into a Material Definitive Agreement | Apr 1, 2025 | ||
| 8-K | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard | Jan 8, 2025 | ||
| 8-K | Changes in Registrant'S Certifying Accountant | Dec 6, 2024 |
Registrations and Prospectuses
| 15-12G | Securities registration termination | Oct 14, 2025 | ||
| S-8 POS | Registration of securities for employees (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 | ||
| S-8 POS | Registration of securities for employees (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 | ||
| S-8 POS | Registration of securities for employees (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 | ||
| POS AM | Prospectus update (post-effective amendment) | Oct 9, 2025 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Aug 22, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Aug 14, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | Jul 22, 2025 | ||
| DEFM14A | Proxy related to merger | Jul 22, 2025 | ||
| DEFA14A | Additional proxy soliciting materials | May 2, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | May 2, 2025 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 22, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Nov 28, 2023 | |
| PRE 14A | Preliminary proxy | Nov 17, 2023 | ||
| DEFA14A | Additional proxy soliciting materials | May 19, 2023 |
Other
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Nov 17, 2025 | ||
| EFFECT | Notice of effectiveness | Apr 5, 2022 | ||
| CORRESP | Correspondence with SEC | Mar 31, 2022 | ||
| CORRESP | Correspondence with SEC | Mar 31, 2022 | ||
| UPLOAD | Letter from SEC | Feb 16, 2022 |
Ownership
| 4 | Avraham Ben-Tzvi | Oct 8, 2025 | ||
| 3 | Gabriel Loh | May 5, 2025 | ||
| 3 | Chay Weei Jye | Apr 16, 2025 | ||
| SC 13D/A | Titan Pharmaceuticals Inc | Aug 21, 2024 | ||
| SC 13D/A | Titan Pharmaceuticals Inc | Apr 5, 2024 | ||
| 3 | Firdauz Mokhtar | Apr 5, 2024 | ||
| 3 | Francisco Flores | Apr 5, 2024 | ||
| 4 | Choon Hau Choong | Mar 27, 2024 | ||
| 4 | David Natan | Oct 26, 2023 | ||
| 4 | Matthew Charles Mcmurdo | Oct 26, 2023 |